Adapted Guidelines for Malaria Case Management in Sudan

Abstract

Background: Malaria is a major public health hazard in Sudan. The latest update to the malaria diagnosis and treatment protocol in  Sudan was in 2017, after which multiple developments in the global guidelines for malaria case management have taken place. Sudan’s  Federal Ministry of Health (FMOH) has updated its malaria case management policy to guide healthcare workers in making informed  decisions about malaria diagnosis, treatment, and prevention.
Methods: The National Malaria Control Program (NMCP) selected a multidisciplinary Technical Advisory Committee (TAC) balanced to  bring together diverse expertise. The committee convened with the NMCP writing team to propose, discuss, and approve updates to the  malaria case management protocol. Protocol updates were prioritized based on the guidelines’ efficacy, safety, and cost-effectiveness. Results: The management guidelines for severe malaria were updated so that parenteral artesunate is the first-line treatment, with  parenteral quinine reserved as second-line therapy. Other updates include the adoption of oral artemetherlumefantrine (AL) as the first- line treatment for uncomplicated malaria in the first trimester of pregnancy. The 2023 protocol upheld the 2017 treatment guidelines for  uncomplicated malaria in other groups, including children, adults, and pregnant women in their second and third trimesters, with AL as  the first-line treatment and dihydroartemisinin-piperaquine (DHAP) as the second-line treatment.
Conclusion: Key changes in the 2023 protocol include updates to the treatment guidelines for severe malaria in all patient groups and  uncomplicated malaria in the first trimester of pregnancy. Future adjustments to the malaria protocol will take place in accordance with  changes in the local context of Sudan as well as global malaria guidelines.